Guardant Health
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Guardant Health sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).
Guardant Health: 9 sponsored US clinical trials, 3 recruiting.
Guardant Health sponsors 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 3 completed. The most-studied condition in this pipeline is Colorectal Cancer, with 3 trials.
Top-decile sponsor footprint
Guardant Health ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
9 total, page 1 of 1
Shield Post-Approval Study Protocol
NCT06880055
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
NCT05935384
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444
Screening for High Frequency Malignant Disease
NCT05117840
Decision Counseling and Follow-up for Shield+ Patients
NCT07620535
Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer
NCT04436393
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
NCT04136002
Guardant360® Test-Related Clinical Outcomes in Patients Who Share Medical Records
NCT03625557
Registry of Guardant360® Use and Outcomes In People With Advanced Cancer
NCT03477474
What is open in the Guardant Health pipeline
3 recruiting of 9 indexed (33% open); 3 completed (33%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Colorectal Cancer (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Guardant Health: open-pipeline peers nationwide
Peers matched on 9 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Guardant Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 9 trials (± recruiting share)
- 4D Molecular Therapeutics · 9 trials · 44% recruiting
- 9 Meters Biopharma · 9 trials · 0% recruiting
- Aadi Bioscience · 9 trials · 33% recruiting
- Ablynx, a Sanofi company · 9 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
- Adagio Medical · 33% recruiting · 3 trials
Related
What to do with this Guardant Health page
9 registered trials is a research-attention snapshot, not an endorsement of Guardant Health or any single study.
- 3 of Guardant Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Colorectal Cancer is the condition Guardant Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Colorectal Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Guardant Health pipeline card: 9 registered trials from official public datasets.Report a data error.